Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat i podpisana zgoda na udział
- •Potwierdzony rozpoznaniem raka trzustki
- •Stwierdzenie przerzutów raka nie wcześniej niż 6 tygodni przed włączeniem do badania
- •Znany status mutacji genu RAS
- •Mierzalne ogniska nowotworu
- •Prawidłowe funkcje narządów (szpik kostny, wątroba, nerki)
- •Możliwość przyjmowania leków w postaci tabletek
✗ Disqualifies
- •Poprzednie leczenie chemioterapią lub lekami celowanymi na RAS w przypadku przerzutów
- •Przerzuty do mózgu, które nie były leczone
- •Schorzenia utrudniające przyjmowanie lub wchłanianie leku
- •Poważna operacja w ciągu ostatnich 4 tygodni
- •Niemożliwość lub brak chęci do uczestnictwa w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (20)
Honor Health Research Institute
Scottsdale, United States
H Lee Moffitt Cancer Center and Research Institute
Tampa, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, United States
Dana-Farber Cancer Institute
Boston, United States
Comprehensive Cancer Centers of Nevada
Henderson, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University of Cincinnati Cancer Center
Cincinnati, United States
Taylor Cancer Research Center
Maumee, United States
SCRI Oncology Partners
Nashville, United States
SCRI - Texas Oncology Dallas
Dallas, United States
MD Anderson Cancer Center
Houston, United States
Virginia Cancer Specialists
Fairfax, United States
Virginia Mason Medical Center
Seattle, United States
Calvary Mater Newcastle
Waratah, Australia
National Cancer Center - East
Kashiwa, Japan
Cancer Institute Hospital - Japan Foundation for Cancer Research
Koto-Ku, Japan
NHO Kyushu Cancer Center
Fukuoka, Japan
Kanagawa Cancer Canter
Kanagawa, Japan
Wakayama Medical University Hospital
Wakayama, Japan
Yamaguchi University Hospital
Yamaguchi, Japan
Trial contact
Revolution Medicines Study Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.